Bolt Biotherapeutics (BOLT) Price & Analysis

Compare

226 Followers

BOLT Stock Chart & Stats

Day’s Range― - ―

52-Week Range$5.20 - $15.62

Previous CloseN/A

Volume72.19K

Average Volume (3M)20.93K

Market Cap

$12.08M

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta0.46

Next Earnings

Aug 06, 2025

EPS Estimate

-6.3

Last Dividend Ex-Date

Aug 29, 2014

Dividend YieldN/A

Share Statistics

EPS (TTM)-5.80

Shares Outstanding1,916,985

10 Day Avg. Volume22,520

30 Day Avg. Volume20,930

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)0.00

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$40.00

Price Target Upside588.47% Upside

Rating ConsensusHold

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Clinical TrialsBolt Biotherapeutics plans to report preliminary Phase 1 data for their lead program targeting Claudin 18.2 in gastric and gastroesophageal cancers, which could demonstrate clinical activity and competitiveness.

Safety ProfileBDC-4182, Bolt's lead program, was tolerated at the highest dose tested in non-human primates, indicating a favorable safety profile.

Bears Say

Competitive LandscapeSeveral peer companies have ongoing or discontinued programs targeting CLDN18.2, indicating a competitive landscape for Bolt Biotherapeutics.

Financial PerformanceBolt reported 4Q24 revenue of $0.0M and EPS of ($0.42), compared to estimates of $0.9M and ($0.34), respectively.

Bolt Biotherapeutics News

Bolt Biotherapeutics Inc trading halted, news pending

19:50 EDT Bolt Biotherapeutics (BOLT) Inc trading halted, news pending Published first on TheFly – the ultimate source...

2M ago

BOLT

Bolt Biotherapeutics Announces Reverse Stock Split

The latest announcement is out from Bolt Biotherapeutics ( ($BOLT) ). On June 6, 2025, Bolt Biotherapeutics implemented...

2M ago

BOLT

Bolt Biotherapeutics Announces Reverse Stock Split Approval

Bolt Biotherapeutics ( ($BOLT) ) has shared an update. On May 27, 2025, Bolt Biotherapeutics‘ Board of Directors...

2M ago

BOLT

Bolt Biotherapeutics Approves Key Governance Changes

Bolt Biotherapeutics ( ($BOLT) ) has issued an update. On May 27, 2025, Bolt Biotherapeutics held its annual...

2M ago

BOLT

Bolt Biotherapeutics initiated with a Buy at Lake Street

Lake Street initiated coverage of Bolt Biotherapeutics (BOLT) with a Buy rating and $4 price target. Bolt has...

2M ago

BOLT

GMAB

Cautious Hold on Bolt Biotherapeutics Amid Awaited Phase 1 Data and Strategic Decisions

JonesTrading analyst Soumit Roy has maintained their neutral stance on BOLT stock, giving a Hold rating on May...

3M ago

BOLT

Cautious Hold Rating on Bolt Biotherapeutics Amid Promising Clinical Data and Financial Uncertainty

Leerink Partners analyst Daina Graybosch has maintained their neutral stance on BOLT stock, giving a Hold rating yesterday....

3M ago

BOLT

Bolt Biotherapeutics price target lowered to $1 from $1.25 at Stifel

Stifel analyst Stephen Willey lowered the firm’s price target on Bolt Biotherapeutics (BOLT) to $1 from $1.25 and...

3M ago

BOLT

Bolt Biotherapeutics Reports Q1 2025 Financial Results

Bolt Biotherapeutics, Inc. ( ($BOLT) ) has released its Q1 earnings. Here is a breakdown of the information...

3M ago

BOLT

Bolt Biotherapeutics reports Q1 EPS (29c), consensus (36c)

Reports Q1 revenue $1.22M, consensus $768K. Reports cash balance of $58.0M as of March 31, which is anticipated...

3M ago

BOLT

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

3M ago

PTN

BOLT

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

3M ago

BOLT

HRTX

Bolt Biotherapeutics to host KOL call on BDC-3042 Phase 1 results

Bolt Biotherapeutics (BOLT) will host a key opinion leader conference call and webcast featuring Ecaterina Dumbrava, M.D., associate...

3M ago

BOLT

Bolt Biotherapeutics announces results for Boltbody ISACs at AACR meeting

Bolt Biotherapeutics (BOLT) announced preclinical results from its next-generation Boltbody ISACs targeting CEACAM5 and PD-L1 at the American...

3M ago

BOLT

BOLT FAQ

What was Bolt Biotherapeutics’s price range in the past 12 months?

Bolt Biotherapeutics lowest stock price was $5.20 and its highest was $15.62 in the past 12 months.

What is Bolt Biotherapeutics’s market cap?

Bolt Biotherapeutics’s market cap is $12.08M.

When is Bolt Biotherapeutics’s upcoming earnings report date?

Bolt Biotherapeutics’s upcoming earnings report date is Aug 06, 2025 which is in 6 days.

How were Bolt Biotherapeutics’s earnings last quarter?

Bolt Biotherapeutics released its earnings results on May 12, 2025. The company reported -$5.8 earnings per share for the quarter, beating the consensus estimate of -$7.1 by $1.3.

Is Bolt Biotherapeutics overvalued?

According to Wall Street analysts Bolt Biotherapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Bolt Biotherapeutics pay dividends?

Bolt Biotherapeutics pays a Quarterly dividend of $0.09 which represents an annual dividend yield of N/A. See more information on Bolt Biotherapeutics dividends here

What is Bolt Biotherapeutics’s EPS estimate?

Bolt Biotherapeutics’s EPS estimate is -6.3.

How many shares outstanding does Bolt Biotherapeutics have?

Bolt Biotherapeutics has 1,916,985 shares outstanding.

What happened to Bolt Biotherapeutics’s price movement after its last earnings report?

Bolt Biotherapeutics reported an EPS of -$5.8 in its last earnings report, beating expectations of -$7.1. Following the earnings report the stock price went down -6.757%.

Which hedge fund is a major shareholder of Bolt Biotherapeutics?

Currently, no hedge funds are holding shares in BOLT

Bolt Biotherapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-83.92%

Trailing 12-Months

Asset Growth

-39.91%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Bolt Biotherapeutics

Bolt Biotherapeutics, Inc. (BOLT) is a clinical-stage biotechnology company focused on developing innovative immuno-oncology therapeutics. The company is pioneering a novel class of immunotherapies known as Boltbody™ Immune-Stimulating Antibody Conjugates (ISACs), designed to harness the power of the innate immune system to fight cancer. Operating primarily in the biotechnology and pharmaceutical sectors, Bolt Biotherapeutics aims to provide transformative cancer treatments that significantly improve patient outcomes.

Bolt Biotherapeutics (BOLT) Earnings & Revenues

BOLT Earnings Data >

BOLT Stock 12 Month Forecast

Average Price Target

$40.00

▲(588.47%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","24":"$24","43":"$43","62":"$62","81":"$81"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":80,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$80.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$40.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,24,43,62,81],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2024","6":"Nov<br/>2024","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6,11.692307692307693,17.384615384615387,23.076923076923077,28.76923076923077,34.46153846153847,40.15384615384615,45.84615384615385,51.53846153846154,57.23076923076923,62.92307692307693,68.61538461538461,74.3076923076923,{"y":80,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6,8.615384615384615,11.23076923076923,13.846153846153847,16.46153846153846,19.076923076923077,21.692307692307693,24.307692307692307,26.923076923076923,29.53846153846154,32.15384615384615,34.769230769230774,37.38461538461539,{"y":40,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6,7.076923076923077,8.153846153846153,9.23076923076923,10.307692307692307,11.384615384615383,12.461538461538462,13.538461538461538,14.615384615384615,15.692307692307692,16.769230769230766,17.846153846153847,18.923076923076923,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":21.4,"date":1696118400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.8,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.2,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.4,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.7,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.17,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":9.8,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":9.49,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.66,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.02,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.11,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >